Global H1N1 (Swine Flu) Vaccination Market Size, Trends and Growth Opportunity, By Vaccine Type (Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccines, Intramuscular, and Toxoid), By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip, and Others) and By End User (Hospitals, Clinics, and Others), By Region and forecast till 2030.
Global H1N1 (Swine Flu) Vaccination Market
Global H1N1 (Swine Flu) Vaccination Market was valued at USD 13.27 billion in 2022 and is slated to reach USD 21.51 billion by 2030 at a CAGR of 6.23% from 2023-2030.
Swine flu is mostly brought on by the H1N1 virus. The nose, lungs, and throat are among the respiratory organs that are affected by the H1N1 virus in terms of function. The H1N1 virus is an orthomyxoviridae family ribonucleic acid (RNA) virus. High fever, body aches, and watery, red, and uncomfortable eyes are all symptoms of the virus. Aside from humans, other species affected by the H1N1 virus include pigs, birds, horses, and other animals. The virus can pass from person to person and is communicable.
Market Drivers
Globally, there are between 290,000 to 650,00 respiratory deaths and 3 to 5 million cases of severe sickness from the flu. Around 8% of people in the United States contract the flu, according to the Centers for Disease Control (CDC). Furthermore, each flu season, some 200,000 additional patients are admitted to hospitals. Thus, the higher uptake of the swine flu vaccine is a result of this rising prevalence. This element promotes market expansion. The market is expanding as a result of the increased demand for intramuscular vaccinations. In the H1N1 vaccines market, the intramuscular vaccinations category commands a sizeable market share and is anticipated to exhibit a trend over the coming years. The market for intramuscular vaccines is expanding as a result of rising swine flu cases and the growing demand for H1N1 inoculation. This contributes to the market's expansion.
Market Restraints
The use of H1N1 (swine flu) vaccine products has several side effects. Effects that are localised, include pain and localised swelling at the immunisation site, decreased appetite and activity, sneezing, slight fever, "snotty nose," and mild coughing. An obstacle to market growth so exists. There are not enough qualified healthcare workers to handle these swine flu cases. There is a very fine line of difference between many viral infections since they frequently mirror one another. Professionals frequently lack the right treatment and fail to recognise the disorders. This contributes to the market barrier. Impact of COVID-19 Many nations have made the distribution of COVID-19 vaccines a priority as a result of the global attention on immunisation that has been brought about by the COVID-19 pandemic. This increasing focus on immunisation may result in greater knowledge of and demand for various vaccinations, including the H1N1 vaccine. However, the methods implemented to stop the transmission of COVID-19, including lockdowns, social isolation, and mask use, have also resulted in a reduction in the spread of other infectious diseases, including H1N1. The demand for the H1N1 vaccine may have dropped as a result of the decrease in the spread of H1N1. The COVID-19 pandemic has also had an impact on the manufacture and distribution of vaccines. The manufacture of H1N1 vaccines has been prioritised over COVID-19 due to supply chain interruptions, limited workforce capacity, and other factors. This might lead to a delay or shortfall in the production of H1N1 vaccines, which would have an impact on the world market.
Market Segmentation
Global H1N1 (Swine Flu) Vaccination Market is segmented into Vaccine Type, Types of Brands, and End-User. By Vaccine Types such as Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccines, Intramuscular, and Toxoid. By Types of Brands such as Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip, and Others. By End-User such as Hospitals, Clinics, and Others.
Regional Analysis
Global H1N1 (Swine Flu) Vaccination Market is segmented into five regions Americas, Europe, Asia-Pacific, and the Middle East & Africa. The H1N1 (swine flu) vaccination market is anticipated to expand in Asia-Pacific during the projected period due to rising virus awareness and an increase in the number of afflicted people. The region's well-developed healthcare infrastructure also contributes to market expansion. North America is expected to dominate the market during the projection period as a result of rising R&D spending. Also, governments are taking several steps to prevent the spread of diseases through various programmes, vaccination drives, and testing supplies, which are fueling market expansion.
Key Players
This report includes a list of numerous Key Players, namely Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), and Baxter. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Virbac (France), Vetoquinol (France).
Market Taxonomy
By Vaccine Type
• Intranasal
• Conjugate
• Attenuated Vaccines
• Inactivated Vaccines
• Intramuscular
• Toxoid
By Type of Brand
• Agripal
• Fiuarix
• Influgen
• Influvac
• Nasovac
• Vaxigrip
• Others
By End User
• Hospitals
• Clinics
• Others
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa.
Global H1N1 (Swine Flu) Vaccination Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global H1N1 (Swine Flu) Vaccination Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn
4.2.6 Post covid-19 world Supply& Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global H1N1 (Swine Flu) Vaccination Market, By Vaccine Type
5.1 Y-o-Y Growth Comparison, By Vaccine Type
5.2 Global H1N1 (Swine Flu) Vaccination Market Share Analysis, By Vaccine Type
5.3 Global H1N1 (Swine Flu) Vaccination Market Size and Forecast, By Vaccine Type
5.3.1 Intranasal
5.3.2 Conjugate
5.3.3 Attenuated Vaccines
5.3.4 Inactivated Vaccines
5.3.5 Intramuscular
5.3.6 Toxoid
6 Global H1N1 (Swine Flu) Vaccination Market, By End User
6.1 Y-o-Y Growth Comparison, By End User
6.2 Global H1N1 (Swine Flu) Vaccination Market Share Analysis, By End User
6.3 Global H1N1 (Swine Flu) Vaccination Market Size and Forecast, By End User
6.3.1 Hospitals
6.3.2 Clinics
6.3.3 Others
7 Global H1N1 (Swine Flu) Vaccination Market, By Type of Brand
7.1 Y-o-Y Growth Comparison, By Type of Brand
7.2 Global H1N1 (Swine Flu) Vaccination Market Share Analysis, By Type of Brand
7.3 Global H1N1 (Swine Flu) Vaccination Market Size and Forecast, By Type of Brand
7.3.1 Agripal
7.3.2 Fiuarix
7.3.3 Influgen
7.3.4 Influvac
7.3.5 Nasovac
7.3.6 Vaxigrip
7.3.7 Others
8 Global H1N1 (Swine Flu) Vaccination Market, By Region
8.1 Global H1N1 (Swine Flu) Vaccination Market Share Analysis, By Region
8.2 Global H1N1 (Swine Flu) Vaccination Market Share Analysis, By Region
8.3 Global H1N1 (Swine Flu) Vaccination Market Size and Forecast, By Region
9 North America H1N1 (Swine Flu) Vaccination Market Analysis and Forecast (2023-2030)
9.1 Introduction
9.2 North America H1N1 (Swine Flu) Vaccination Market Share Analysis, By Vaccine Type
9.3 North America H1N1 (Swine Flu) Vaccination Market Size and Forecast, By End User
9.4 North America H1N1 (Swine Flu) Vaccination Market Size and Forecast, By Type of Brand
9.5 North America H1N1 (Swine Flu) Vaccination Market Size and Forecast, By Country
9.5.1 U.S.
10.5.2 Canada
10.5.3 Mexico
10 Europe H1N1 (Swine Flu) Vaccination Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 Europe H1N1 (Swine Flu) Vaccination Market Share Analysis, By Vaccine Type
10.3 Europe H1N1 (Swine Flu) Vaccination Market Size and Forecast, By End User
10.4 Europe H1N1 (Swine Flu) Vaccination Market Size and Forecast, By Type of Brand
10.5 Europe H1N1 (Swine Flu) Vaccination Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.5.4. Rest of Europe
11 Asia Pacific H1N1 (Swine Flu) Vaccination Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Asia Pacific H1N1 (Swine Flu) Vaccination Market Share Analysis, By Vaccine Type
11.3 Asia Pacific H1N1 (Swine Flu) Vaccination Market Size and Forecast, By End User
11.4 Asia Pacific H1N1 (Swine Flu) Vaccination Market Size and Forecast, By Type of Brand
11.5 Asia Pacific H1N1 (Swine Flu) Vaccination Market Size and Forecast, By Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4. Rest of Asia Pacific
13 Latin America H1N1 (Swine Flu) Vaccination Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Latin America H1N1 (Swine Flu) Vaccination Market Share Analysis, By Vaccine Type
13.3 Latin America H1N1 (Swine Flu) Vaccination Market Size and Forecast, By Type of Brand
13.4 Latin America H1N1 (Swine Flu) Vaccination Market Size and Forecast, By End User
13.5 Latin America H1N1 (Swine Flu) Vaccination Market Size and Forecast, Country
13.5.1. Brazil
13.5.2. Rest of Latin America
14 Middle East H1N1 (Swine Flu) Vaccination Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Middle East H1N1 (Swine Flu) Vaccination Market Share Analysis, By Vaccine Type
14.3 Middle East H1N1 (Swine Flu) Vaccination Market Size and Forecast, By End User
14.4 Middle East H1N1 (Swine Flu) Vaccination Market Size and Forecast, By Type of Brand
14.5 Middle East H1N1 (Swine Flu) Vaccination Market Size and Forecast, By Country
14.5.1. Saudi Arabia
14.5.2. UAE
14.5.3. Egypt
14.5.4. Kuwait
14.5.5. South Africa
15 Competitive Analysis
15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16 Company Profiles
16.1 Sanofi (France)
16.1.1 Overview
16.1.2 Products
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2 Pfizer Inc. (U.S.)
16.2.1 Overview
16.2.2 Products
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3 GSK plc (U.K.)
16.3.1 Overview
16.3.2 Products
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 Novartis AG (Switzerland)
16.4.1 Overview
16.4.2 Products
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 Mylan N.V. (U.S.)
16.5.1 Overview
16.5.2 Products
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 Baxter. (U.S.)
16.6.1 Overview
16.6.2 Products
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 AstraZeneca (U.K.)
16.7.1 Overview
16.7.2 Products
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies
16.8 Johnson & Johnson Private Limited (U.S.)
16.8.1 Overview
16.8.2 Products
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
16.9 Virbac (France)
16.9.1 Overview
16.9.2 Products
16.9.3 Key Financials
16.9.4 Business Segment & Geographic Overview
16.9.5 Key Market Developments
16.9.6 Key Strategies
16.10 Vetoquinol (France)
16.10.1 Overview
16.10.2 Products
16.10.3 Key Financials
16.10.4 Business Segment & Geographic Overview
16.10.5 Key Market Developments
16.10.6 Key Strategies
